secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001193125-24-230144
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres completes VOWST sale to Nestlé for ~$175M gross; debt retired, runway to Q4 2025
--------------------------------------------------------------------------------

- Received ~$175M gross at close: $100M upfront, $60M prepaid milestone, $15M equity; net ~$155M after ~$20M settlement.
- Repaid $128M to Oaktree, terminating $110M term loan; debt fully retired.
- Expects $50M installment in Jan 2025, $25M in July 2025; up to $275M future milestones tied to VOWST sales.
- Focus shifts to SER-155 (promising Phase 1b allo-HSCT data), SER-147; headcount cut from ~200 to ~100.
- Cash runway extended into Q4 2025; plans to seek Breakthrough Therapy designation for SER-155.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524230144/0001193125-24-230144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312524230144/d873729d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-230144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer